Colon CancerNCT01991080
The Relationship Between Relaxation or Wheat Germ Juice to the Immune Indices and Quality of Life (QoL) in Colorectal Cancer Patients on Adjuvant Chemotherapy
A study testing biofeedback and Wheatgerm juice in people with Colon Cancer, run by Rambam Health Care Campus at 1 site in Israel.
Trial summary
The immune system plays an important role in the fight against cancer. According to certain studies, Levels of cytokines secreted by the immune cells were found as predictors of prognosis and survival among cancer patients, as well as disease recurrence. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Colon Cancer
- What is being tested?
- biofeedback and Wheatgerm juice
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteIsrael
- Study dates
- Dec 2013to Dec 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- colon cancer patients receiving adjuvant treatment as described above after hysterectomy surgery.
- stage II or III disease
- age over 18 years.
- functional status (PS) ≤ 2 (0-2 WHO performance status)
- patients hospital Rambam Medical Center6. signing of the informed consent form
Who cannot join
- patients taking psychiatric drugs because of depression, anxiety or another disorder that requires psychiatric intervention.
- comorbidity that directly affects the immune indices (such as autoimmune diseases, immune deficiency)3. difficulty in understanding the Hebrew language-these patients can be included in the control group
Trial locations and contacts
1 site in 1 country.
Israel1 site, 1 recruiting
- Recruiting
Oncology Institute, Rambam Health Care Campus
Haifa, 31096
Gil Bar Sela, Prof, +972-4-8542791, g_barsela@rambam.health.gov.il
Gil Bar Sela, Prof
About this study
Official title: Examining the Relationship Between Relaxation Combined With Biofeedback or Wheat Germ Juice to the Immune Indices and Quality of Life Measures in Patients With Colorectal Cancer Who Receive Prophylactic Chemotherapy After Surgery
The immune system plays an important role in the fight against cancer. According to certain studies, Levels of cytokines secreted by the immune cells were found as predictors of prognosis and survival among cancer patients, as well as disease recurrence. Previous studies, including meta-analyses, reported that chronic emotional stress or depression were associated with higher levels of pro-inflammatory cytokines. Practicing relaxation was found to decrease psychological symptoms among cancer patients, such as depression, anger, hostility and anxiety symptoms, as well as physical symptoms.
Wheatgrass juice is an extract squeezed from the mature sprouts of wheat seeds (Triticum aestivum). Currently, there are only a few laboratory and medical studies that examine the beneficial effects of wheatgrass consumption. Controlled clinical trials have found that wheatgrass juice may reduce chemotherapy-induced myelotoxicity, accompanied by fever and infection without harming the chemotherapy effectiveness among breast cancer patients6.
Read more
Aims
- To examine the differences in immune measures (serum and micro-particles levels of the cytokines IL-6, IL-8, IL-10 and IL-12), and in physical and psychological well-being measures (anxiety, depression, pain, fatigue, nausea) at three time points and between two intervention methods (biofeedback-assisted relaxation and wheatgrass consumption) and between the intervention groups vs. a control group, among colorectal cancer patients.
- To assess the mediating role of optimism, perceived control and well-being measures (anxiety, depression, pain, fatigue, nausea) among colorectal cancer patients in the relations between the interventions (biofeedback-assisted relaxation and wheatgrass consumption) and the immune measures (serum and micro-particles levels of cytokines IL-6, IL-8 IL-10 and IL-12 ), and the mediating role of well-being measures on the relations between optimism and perceived control with immune measures.
Methods Participants will include 120 colorectal cancer patients aged 18+, with Eastern performance status of ≤ 2 and disease stage II or III, who receive adjuvant chemotherapy of Capcitabine or FU-5 treatment, conjoined with Oxaliplatin, or Capcitabine alone following curative surgery at Rambam Health Care Campus. The estimated number of participants was calculated based on Green's equation (1991): 50+8X 7 A comparison between the two treatment groups, as well as a comparison between each treatment group and the control group (80 subjects) will allow inclusion of up to four background parameters in each of the regressions, according to Green's equation.
Read the detailed description
The immune system plays an important role in the fight against cancer. According to certain studies, Levels of cytokines secreted by the immune cells were found as predictors of prognosis and survival among cancer patients, as well as disease recurrence1. Pro-inflammatory cytokines, such as IL-6, IL-8 and IL-10 were found to be negative prognostic factors in different cancer types, including colorectal cancer, while IL-12 was found in several studies to be a positive prognostic factor. However, inconclusive results were found for the role of IL-12 and anti-inflammatory cytokines in cancer prognosis.
Previous studies, including meta-analyses, reported that chronic emotional stress or depression were associated with higher levels of pro-inflammatory cytokines2; furthermore, there is some, albeit inconclusive, evidence that they may predict lower survival rates3. Moreover, there is further evidence that personal resources such as optimism and control perceptions may have an effect on psychological and physical well-being (i.e., low level of psychological or physical symptoms in reaction to stressful events) and dysregulate immune functions such as levels of pro-inflammatory cytokines.
Practicing relaxation was found to decrease psychological symptoms among cancer patients, such as depression, anger, hostility and anxiety symptoms, as well as physical symptoms, including fatigue, insomnia and pain. In addition, relaxation may reduce nausea and vomiting following chemotherapy.
Several studies of cancer patients have reported positive associations between relaxation-based interventions and immune measures, such as an elevated rate of T-cell subpopulations as well as increased IL-4 production and decreased IL-10 production4. Similarly, biofeedback-assisted relaxation was associated with enhanced natural killer cell activity, lymphocyte responsiveness, and the number of peripheral blood lymphocytes5. However, results are not always conclusive, and the few studies investigating the relationship between relaxation training and immune measures have often included small and uncontrolled samples.
Wheatgrass juice is an extract squeezed from the mature sprouts of wheat seeds (Triticum aestivum). Currently, there are only a few laboratory and medical studies that examine the beneficial effects of wheatgrass consumption. These studies tend to report positive effects with minimal side effects among patients with arthritis, thalassemia and ulcerative colitis. Lab research has demonstrated that wheatgrass consumption caused a prolonged latent period of skin cancer in mice. Controlled clinical trials have found that wheatgrass juice may reduce chemotherapy-induced myelotoxicity, accompanied by fever and infection without harming the chemotherapy effectiveness among breast cancer patients6.
Aims
In light of the lack of studies examining the effects of wheatgrass consumption on immune and well-being measures, as well as limited data from few studies regarding the effects of biofeedback-assisted relaxation on immune parameters, the aims of the current study are as follow:
- To examine the differences in immune measures (serum and micro-particles levels of the cytokines IL-6, IL-8, IL-10 and IL-12), and in physical and psychological well-being measures (anxiety, depression, pain, fatigue, nausea) at three time points and between two intervention methods (biofeedback-assisted relaxation and wheatgrass consumption) and between the intervention groups vs. a control group, among colorectal cancer patients.
- To assess the mediating role of optimism, perceived control and well-being measures (anxiety, depression, pain, fatigue, nausea) among colorectal cancer patients in the relations between the interventions (biofeedback-assisted relaxation and wheatgrass consumption) and the immune measures (serum and micro-particles levels of cytokines IL-6, IL-8 IL-10 and IL-12 ), and the mediating role of well-being measures on the relations between optimism and perceived control with immune measures.
Methods Participants will include 120 colorectal cancer patients aged 18+, with Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 and disease stage II or III, who receive adjuvant chemotherapy of Capecitabine (Xeloda) or FU-5 treatment, conjoined with Oxaliplatin, or Capecitabine alone following curative surgery at Rambam Health Care Campus. The estimated number of participants was calculated based on Green's equation (1991): 50+8X 7 (The Regression Model requires 50 participants + 8 participants for each variable). Possible parameters that will be monitored using the regression analysis will be: age, gender, blood Albumin level, morbidity (including: diabetes, hypertension, heart disease, stroke, arthritis), optimism and control perception. A comparison between the two treatment groups, as well as a comparison between each treatment group and the control group (80 subjects) will allow inclusion of up to four background parameters in each of the regressions, according to Green's equation. Due to the large number of background parameters that can be potential confounding variables, only parameters with significant association to the dependent variables will be included. In the univariate statistical analysis, analysis of variance (ANOVA) will be conducted in order to compare the study groups. In addition, a comparison of outcome parameters before and after the intervention period will be conducted using paired t-tests and Repeated measure analysis. As the calculated sample size and the statistical power are sufficient for the regression analysis (multivariate statistical analysis), they are also suitable for the univariate statistical analysis.
Following recruitment, participants will be randomly divided into 2 intervention groups: biofeedback-assisted relaxation or wheatgrass consumption. The control group will consist of subjects who were not interested in participating in the active intervention, but agreed to contribute blood samples during chemotherapy treatments for the purpose of the study. This study design was selected as expected recruitment rate will not allow for a random allocation for test and control groups. However, this control will enable us to compare immune parameters of patients who refused to participate in this study, with those who were allocated to each group, in order to neutralize the effect of the oncology treatment and to compare the groups. In addition, each treatment group can be evaluated for immune and well-being parameters, each subject's pre-treatment status serving as a control for his post-treatment status.
Blood samples will be collected at baseline (the onset of chemotherapy), and then again 3 and 6 months later for measuring the levels of cytokines (IL-6, IL-8, IL-10, IL-12) in the serum and in micro-particles. Well-being will be assessed at the same 3 time points via questionnaires, including emotional and physical symptoms: anxiety, depression, pain, nausea and vomiting, and chronic fatigue levels. Demographical and medical information will be taken from the medical records. The two study interventions will continue for 6 months (the chemotherapy treatment period). (1) Biofeedback-assisted relaxation intervention group: participants will receive biofeedback devices to practice relaxation at home. Four sessions will be conducted with a psychologist specializing in biofeedback therapy. During these sessions, relaxation techniques will be learned and practiced. (2) Wheatgrass intervention group: Each patient will be supplied with frozen wheatgrass juice divided into daily doses of 60 cc. Patients will be asked to drink one dose every morning on an empty stomach.
Study importance and potential contribution This is a first study to examine the possible effects of biofeedback-assisted relaxation vs. wheatgrass juice on immune and well-being parameters among colorectal cancer patients. To the best of our knowledge, this is the first study to investigate the possible effects of biofeedback-assisted relaxation on serum levels of the pro-inflammatory cytokines. Using a randomized controlled design with three time points and a homogenous sample in terms of disease parameters, type of treatment and functional status will allow us to obtain valid results regarding the psychological and physical parameters of well-being and pro-inflammatory biomarkers. Possible verification of the study hypotheses will add to the theoretical knowledge on the effects of personal resources and psychological well-being on immune measures and may suggest potential ways to improve well-being as well as cancer-related symptoms, and even disease course among colorectal cancer patients
- Conditions
- Colon Cancer
- Being tested
- biofeedback, Wheatgerm juice
- Keywords
- biofeedback, relaxation, Wheat germ juice
- Medical subject headings
- Colonic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
biofeedbackBehavioural
Also called Patients will go through biofeedback sessions
Patients will go through biofeedback sessions
Wheatgerm juiceDrug
Also called Patient will drink wheatgerm juice
Patient will drink wheatgerm juice
| Study group | Role | What they receive |
|---|---|---|
| Wheatgerm juice | Active comparator | patients will drink Wheatgerm juice Receives: Behavioral: biofeedback; Drug: Wheatgerm juice |
| Biofeedback | Active comparator | The patients will undergo biofeedback relaxation therapy Receives: Behavioral: biofeedback; Drug: Wheatgerm juice |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary Outcome
1.The differences in the level of the inflammatory cytokines IL-6, 8-6, IL10, IL-12, in serum and microparticles.
between two methods of intervention (relaxation in combination with biofeedback or wheatgrass juice consumption) or control group of patients with colorectal cancer under chemotherapy adjuvant treatment.
Measured: six months or end of adjuvant chemotherapy
Secondary outcomes (3)
Secondary
Quality of life according to Q30-EORTC between two methods of intervention (relaxation in combination with biofeedback or wheatgrass juice consumption) or control group of patients with colorectal cancer under chemotherapy adjuvant treatment.
Measured: six months or end of adjuvant chemotherapy treatment
secondary
Depression according to HADS questionaire between two methods of intervention (relaxation in combination with biofeedback or wheatgrass juice consumption) or control group of patients with colorectal cancer under chemotherapy adjuvant treatment.
Measured: six months or end of adjuvant chemotherapy
secondary
Anxiety according HADS questionaire between two methods of intervention (relaxation in combination with biofeedback or wheatgrass juice consumption) or control group of patients with colorectal cancer under chemotherapy adjuvant treatment.
Measured: Six months or end of adjuvant chemotherapy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Nov 2013 (estimated)
- Study startDec 2013
- Primary completionDec 2018 (estimated)
- Study completionDec 2018 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colon CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Rambam Health Care Campus
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Gil Bar-Sela, MD, Principal investigator, Rambam Health Care Campus
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01991080
- Sponsor's protocol ID
- Biofeedback
- Status last verified
- May 2017
- First submitted
- 29 Oct 2013
- Last updated
- 8 May 2017
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Examining the Relationship Between Relaxation Combined With Biofeedback or Wheat Germ Juice to the Immune Indices and Quality of Life Measures in Patients With Colorectal Cancer Who Receive Prophylactic Chemotherapy After Surgery
- ClinicalTrials.gov ID
- NCT01991080
- Acronym / sponsor ID
- Biofeedback
- Conditions
- Colon Cancer
- Keywords
- biofeedback, relaxation, Wheat germ juice
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Rambam Health Care CampusUniversity, hospital or other
- Study start
- Dec 2013
- Primary completion
- Dec 2018 (estimated)
- Study completion
- Dec 2018 (estimated)
- First posted
- 25 Nov 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The immune system plays an important role in the fight against cancer. According to certain studies, Levels of cytokines secreted by the immune cells were found as predictors of prognosis and survival among cancer patients, as well as disease recurrence. Previous studies, including meta-analyses, reported that chronic emotional stress or depression were associated with higher levels of pro-inflammatory cytokines. Practicing relaxation was found to decrease psychological symptoms among cancer patients, such as depression, anger, hostility and anxiety symptoms, as well as physical symptoms.
Wheatgrass juice is an extract squeezed from the mature sprouts of wheat seeds (Triticum aestivum). Currently, there are only a few laboratory and medical studies that examine the beneficial effects of wheatgrass consumption. Controlled clinical trials have found that wheatgrass juice may reduce chemotherapy-induced myelotoxicity, accompanied by fever and infection without harming the chemotherapy effectiveness among breast cancer patients6.
Aims
- To examine the differences in immune measures (serum and micro-particles levels of the cytokines IL-6, IL-8, IL-10 and IL-12), and in physical and psychological well-being measures (anxiety, depression, pain, fatigue, nausea) at three time points and between two intervention methods (biofeedback-assisted relaxation and wheatgrass consumption) and between the intervention groups vs. a control group, among colorectal cancer patients.
- To assess the mediating role of optimism, perceived control and well-being measures (anxiety, depression, pain, fatigue, nausea) among colorectal cancer patients in the relations between the interventions (biofeedback-assisted relaxation and wheatgrass consumption) and the immune measures (serum and micro-particles levels of cytokines IL-6, IL-8 IL-10 and IL-12 ), and the mediating role of well-being measures on the relations between optimism and perceived control with immune measures.
Methods Participants will include 120 colorectal cancer patients aged 18+, with Eastern performance status of ≤ 2 and disease stage II or III, who receive adjuvant chemotherapy of Capcitabine or FU-5 treatment, conjoined with Oxaliplatin, or Capcitabine alone following curative surgery at Rambam Health Care Campus. The estimated number of participants was calculated based on Green's equation (1991): 50+8X 7 A comparison between the two treatment groups, as well as a comparison between each treatment group and the control group (80 subjects) will allow inclusion of up to four background parameters in each of the regressions, according to Green's equation.
Detailed description
The immune system plays an important role in the fight against cancer. According to certain studies, Levels of cytokines secreted by the immune cells were found as predictors of prognosis and survival among cancer patients, as well as disease recurrence1. Pro-inflammatory cytokines, such as IL-6, IL-8 and IL-10 were found to be negative prognostic factors in different cancer types, including colorectal cancer, while IL-12 was found in several studies to be a positive prognostic factor. However, inconclusive results were found for the role of IL-12 and anti-inflammatory cytokines in cancer prognosis.
Previous studies, including meta-analyses, reported that chronic emotional stress or depression were associated with higher levels of pro-inflammatory cytokines2; furthermore, there is some, albeit inconclusive, evidence that they may predict lower survival rates3. Moreover, there is further evidence that personal resources such as optimism and control perceptions may have an effect on psychological and physical well-being (i.e., low level of psychological or physical symptoms in reaction to stressful events) and dysregulate immune functions such as levels of pro-inflammatory cytokines.
Practicing relaxation was found to decrease psychological symptoms among cancer patients, such as depression, anger, hostility and anxiety symptoms, as well as physical symptoms, including fatigue, insomnia and pain. In addition, relaxation may reduce nausea and vomiting following chemotherapy.
Several studies of cancer patients have reported positive associations between relaxation-based interventions and immune measures, such as an elevated rate of T-cell subpopulations as well as increased IL-4 production and decreased IL-10 production4. Similarly, biofeedback-assisted relaxation was associated with enhanced natural killer cell activity, lymphocyte responsiveness, and the number of peripheral blood lymphocytes5. However, results are not always conclusive, and the few studies investigating the relationship between relaxation training and immune measures have often included small and uncontrolled samples.
Wheatgrass juice is an extract squeezed from the mature sprouts of wheat seeds (Triticum aestivum). Currently, there are only a few laboratory and medical studies that examine the beneficial effects of wheatgrass consumption. These studies tend to report positive effects with minimal side effects among patients with arthritis, thalassemia and ulcerative colitis. Lab research has demonstrated that wheatgrass consumption caused a prolonged latent period of skin cancer in mice. Controlled clinical trials have found that wheatgrass juice may reduce chemotherapy-induced myelotoxicity, accompanied by fever and infection without harming the chemotherapy effectiveness among breast cancer patients6.
Aims
In light of the lack of studies examining the effects of wheatgrass consumption on immune and well-being measures, as well as limited data from few studies regarding the effects of biofeedback-assisted relaxation on immune parameters, the aims of the current study are as follow:
- To examine the differences in immune measures (serum and micro-particles levels of the cytokines IL-6, IL-8, IL-10 and IL-12), and in physical and psychological well-being measures (anxiety, depression, pain, fatigue, nausea) at three time points and between two intervention methods (biofeedback-assisted relaxation and wheatgrass consumption) and between the intervention groups vs. a control group, among colorectal cancer patients.
- To assess the mediating role of optimism, perceived control and well-being measures (anxiety, depression, pain, fatigue, nausea) among colorectal cancer patients in the relations between the interventions (biofeedback-assisted relaxation and wheatgrass consumption) and the immune measures (serum and micro-particles levels of cytokines IL-6, IL-8 IL-10 and IL-12 ), and the mediating role of well-being measures on the relations between optimism and perceived control with immune measures.
Methods Participants will include 120 colorectal cancer patients aged 18+, with Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 and disease stage II or III, who receive adjuvant chemotherapy of Capecitabine (Xeloda) or FU-5 treatment, conjoined with Oxaliplatin, or Capecitabine alone following curative surgery at Rambam Health Care Campus. The estimated number of participants was calculated based on Green's equation (1991): 50+8X 7 (The Regression Model requires 50 participants + 8 participants for each variable). Possible parameters that will be monitored using the regression analysis will be: age, gender, blood Albumin level, morbidity (including: diabetes, hypertension, heart disease, stroke, arthritis), optimism and control perception. A comparison between the two treatment groups, as well as a comparison between each treatment group and the control group (80 subjects) will allow inclusion of up to four background parameters in each of the regressions, according to Green's equation. Due to the large number of background parameters that can be potential confounding variables, only parameters with significant association to the dependent variables will be included. In the univariate statistical analysis, analysis of variance (ANOVA) will be conducted in order to compare the study groups. In addition, a comparison of outcome parameters before and after the intervention period will be conducted using paired t-tests and Repeated measure analysis. As the calculated sample size and the statistical power are sufficient for the regression analysis (multivariate statistical analysis), they are also suitable for the univariate statistical analysis.
Following recruitment, participants will be randomly divided into 2 intervention groups: biofeedback-assisted relaxation or wheatgrass consumption. The control group will consist of subjects who were not interested in participating in the active intervention, but agreed to contribute blood samples during chemotherapy treatments for the purpose of the study. This study design was selected as expected recruitment rate will not allow for a random allocation for test and control groups. However, this control will enable us to compare immune parameters of patients who refused to participate in this study, with those who were allocated to each group, in order to neutralize the effect of the oncology treatment and to compare the groups. In addition, each treatment group can be evaluated for immune and well-being parameters, each subject's pre-treatment status serving as a control for his post-treatment status.
Blood samples will be collected at baseline (the onset of chemotherapy), and then again 3 and 6 months later for measuring the levels of cytokines (IL-6, IL-8, IL-10, IL-12) in the serum and in micro-particles. Well-being will be assessed at the same 3 time points via questionnaires, including emotional and physical symptoms: anxiety, depression, pain, nausea and vomiting, and chronic fatigue levels. Demographical and medical information will be taken from the medical records. The two study interventions will continue for 6 months (the chemotherapy treatment period). (1) Biofeedback-assisted relaxation intervention group: participants will receive biofeedback devices to practice relaxation at home. Four sessions will be conducted with a psychologist specializing in biofeedback therapy. During these sessions, relaxation techniques will be learned and practiced. (2) Wheatgrass intervention group: Each patient will be supplied with frozen wheatgrass juice divided into daily doses of 60 cc. Patients will be asked to drink one dose every morning on an empty stomach.
Study importance and potential contribution This is a first study to examine the possible effects of biofeedback-assisted relaxation vs. wheatgrass juice on immune and well-being parameters among colorectal cancer patients. To the best of our knowledge, this is the first study to investigate the possible effects of biofeedback-assisted relaxation on serum levels of the pro-inflammatory cytokines. Using a randomized controlled design with three time points and a homogenous sample in terms of disease parameters, type of treatment and functional status will allow us to obtain valid results regarding the psychological and physical parameters of well-being and pro-inflammatory biomarkers. Possible verification of the study hypotheses will add to the theoretical knowledge on the effects of personal resources and psychological well-being on immune measures and may suggest potential ways to improve well-being as well as cancer-related symptoms, and even disease course among colorectal cancer patients
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Wheatgerm juice | Active comparator | Behavioral: biofeedback, Drug: Wheatgerm juicepatients will drink Wheatgerm juice |
| Biofeedback | Active comparator | Behavioral: biofeedback, Drug: Wheatgerm juiceThe patients will undergo biofeedback relaxation therapy |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- colon cancer patients receiving adjuvant treatment as described above after hysterectomy surgery.
- stage II or III disease
- age over 18 years.
- functional status (PS) ≤ 2 (0-2 WHO performance status)
- patients hospital Rambam Medical Center6. signing of the informed consent form
Key exclusion criteria (2 listed)
- patients taking psychiatric drugs because of depression, anxiety or another disorder that requires psychiatric intervention.
- comorbidity that directly affects the immune indices (such as autoimmune diseases, immune deficiency)3. difficulty in understanding the Hebrew language-these patients can be included in the control group
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| biofeedbackAlso: Patients will go through biofeedback sessionsPatients will go through biofeedback sessions | Behavioural | Biofeedback, Wheatgerm juice |
| Wheatgerm juiceAlso: Patient will drink wheatgerm juicePatient will drink wheatgerm juice | Drug | Biofeedback, Wheatgerm juice |
Primary outcome
Primary Outcome
Time frame: six months or end of adjuvant chemotherapy
1.The differences in the level of the inflammatory cytokines IL-6, 8-6, IL10, IL-12, in serum and microparticles. between two methods of intervention (relaxation in combination with biofeedback or wheatgrass juice consumption) or control group of patients with colorectal cancer under chemotherapy adjuvant treatment.
3 secondary outcomes
Secondary
Time frame: six months or end of adjuvant chemotherapy treatment
secondary
Time frame: six months or end of adjuvant chemotherapy
secondary
Time frame: Six months or end of adjuvant chemotherapy
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2017.
- Individual participant dataSharing planned: No
Related trials for Colon Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Not yet recruitingPhase 2
Alberta Cancer Exercise Dose in Colorectal Cancer
Cancer, Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Oncology Institute, Rambam Health Care Campus
Haifa, Israel
Gil Bar-Sela, MD principal investigator
Rambam Health Care Campus
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing biofeedback and Wheatgerm juice in people with Colon Cancer, run by Rambam Health Care Campus at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 8 May 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary Outcome (time frame: six months or end of adjuvant chemotherapy). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2017.